Cathelicidin (CAMP) (NM_004345) Human Tagged ORF Clone Lentiviral Particle
CAT#: RC208872L2V
- LentiORF®
Lenti ORF particles, CAMP (mGFP-tagged) - Human cathelicidin antimicrobial peptide (CAMP), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 8,360.00
货期*
详询
规格
Product images
经常一起买 (3)
Specifications
Product Data | |
Product Name | Cathelicidin (CAMP) (NM_004345) Human Tagged ORF Clone Lentiviral Particle |
Synonyms | CAP-18; CAP18; CRAMP; FALL-39; FALL39; HSD26; LL37 |
Vector | pLenti-C-mGFP |
ACCN | NM_004345 |
ORF Size | 510 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(RC208872).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_004345.3 |
RefSeq Size | 758 bp |
RefSeq ORF | 513 bp |
Locus ID | 820 |
Domains | Cathelicidins |
Protein Families | Secreted Protein, Transmembrane |
MW | 19.3 kDa |
Gene Summary | This gene encodes a member of an antimicrobial peptide family, characterized by a highly conserved N-terminal signal peptide containing a cathelin domain and a structurally variable cationic antimicrobial peptide, which is produced by extracellular proteolysis from the C-terminus. In addition to its antibacterial, antifungal, and antiviral activities, the encoded protein functions in cell chemotaxis, immune mediator induction, and inflammatory response regulation. [provided by RefSeq, Sep 2014] |
Documents
Product Manuals |
FAQs |
SDS |
Resources
You may also need
其它Cathelicidin产品
Customer
Reviews
Loading...